Clinical trials: Breast Neoplasms, completed
Breast Cancer, Nausea and Vomiting
The Impact of Oral Cryotherapy and Chewing Gum Interventions
Chemotherapy-induced nausea and vomiting (CINV) and taste alterations continue to be among the most common and most severe side effects that women receiving adjuvant chemotherapy for breast cancer suffer.
- Conditions
- Breast Cancer, Nausea and Vomiting, Quality of Life, Chewing Gum
- Trial name
- NCT07145320
- Testing
- Oral Cryotherapy Group (Group 1), Chewing Gum Group (Group 2)
- Where
- Turkey (Türkiye)
- Volunteers
- 135 people
- Sponsor
- Hacettepe University
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Recurrent Breast Cancer, Stage IV Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
Phase II trial to study the effectiveness of combination chemotherapy with or without trastuzumab in treating women who have metastatic breast cancer.
- Trial name
- NCT00004888
- Testing
- pegylated liposomal doxorubicin hydrochloride, docetaxel, trastuzumab
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Adherence to Intensive Surveillance for Hereditary Breast Cancer
Women with strong family histories of breast cancer are at increased risk to have breast cancer. Women whose close relatives have had breast cancer often have more breast cancer screening than other women their age.
- Trial name
- NCT00582803
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
ER+ HER2- Advanced Breast Cancer
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer
This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD9833 in Japanese women with endocrineresistant ER+ HER2- breast cancer that is not amenable to…
- Trial name
- NCT04541433
- Testing
- AZD9833
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Breast Cancer
Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer
Explore the efficacy and safety of the combination of inetetamab, pyrotinib and nab-paclitaxel in the neoadjuvant treatment of HER2 positive early or locally advanced breast cancer
- Trial name
- NCT05444998
- Testing
- Inetetamab, pyrotinib, nab-paclitaxel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
Breast Cancer
Radiologic Evaluation and Breast Density (READ)
The purpose of this study is to determine whether cessation of hormone replacement therapy for one or two months before a screening mammogram will improve its performance by decreasing breast density.
- Trial name
- NCT00117663
- Testing
- temporary discontinuation of hormone therapy for 1 month, temporary discontinuation of hormone therapy for 2 months
- Where
- United States
- Volunteers
- 1,704 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Breast Cancer, Hormone Receptor Positive Tumor
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
The purpose of this study is to evaluate the efficacy and quality of life in women with advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the breast), HR+ / HER2-, who are treated with an…
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- INGE-B (NCT02894398)
- Testing
- Palbociclib, Letrozole, Anastrozole
- Where
- 70 sites in Germany
- Volunteers
- 388 people
- Sponsor
- iOMEDICO AG
Breast Cancer
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, docetaxel,, paclitaxel, and ixabepilone work in different ways to stop the growth of tumor cells, either by killing the cells…
- Trial name
- NCT00637897
- Testing
- docetaxel, ixabepilone, paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Cancer Survivor, Stage I Breast Cancer AJCC v7
Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors.
- Conditions
- Cancer Survivor, Stage I Breast Cancer AJCC v7, Stage I Colon Cancer AJCC v6 and v7, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT03407716
- Testing
- American Ginseng, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Fear of Cancer Recurrence
The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence
The primary aim of this study is to assess the effect of ConquerFear, a metacognition-based manualized intervention on fear of cancer recurrence, using the randomized controlled trial approach, among Chinese patients newly…
- Trial name
- NCT04568226
- Testing
- ConquerFear Intervention, Active control: Basic Cancer Care
- Where
- 6 sites in Hong Kong
- Volunteers
- 177 people
- Sponsor
- The University of Hong Kong
Metastatic Breast Cancer, Brain Metastases
Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer
Objectives: Primary - Determine the maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLT) of combining lapatinib and temozolomideSecondary - Obtain preliminary information on the clinical anti-tumor…
- Conditions
- Metastatic Breast Cancer, Brain Metastases, HER2 Positive
- Trial name
- LAPTEM (NCT00614978)
- Testing
- lapatinib and temozolomide
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Jules Bordet Institute
Breast Cancer
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a Phase I/randomized Phase II study design in order to test the tolerability and efficacy of AZD0530 (also called saracatinib) when used together with anastrozole in therapy for ER+ and/or…
- Trial name
- NCT01216176
- Testing
- Anastrozole, AZD0530 (saracatinib)
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Joyce Marie Slingerland, MD
Breast Cancer
Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
Some tumors use estrogen in the body to assist with growth. Letrozole is a drug that is prevents cells from producing estrogens. This should assist with the slowing of growth of tumor cells.
- Trial name
- NCT02010021
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography
The primary hypothesis to be tested is: The detection of breast cancer will be increased with tomosynthesis (3D) imaging
- Trial name
- NCT01669148
- Testing
- Tomosynthesis, Conventional
- Where
- United States
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Breast Cancer Female
Hypofractionated Radiation Therapy With Concomitant Boost in Treating Women After Breast Conserving Surgery
This phase II study is to evaluate the safety of hypofractionated whole breast radiation (HFRT) with simultaneous tumor bed boost(SIB) in women with early breast cancer after breast-conserving surgery.
- Trial name
- NCT03320421
- Testing
- Radiation therapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese Academy of Medical Sciences
Malignant Neoplasm of Breast Stage IV
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
This retrospective observational study is designed to assess the response to treatment with fulvestrant at a dose of 500 mg/month with a loading dose of 500 mg (LD-500), in terms of progression free survival (PFS), overall…
- Trial name
- EFFICACY (NCT01509625)
- Testing
- Fulvestrant
- Where
- 7 sites in Spain
- Volunteers
- 272 people
- Sponsor
- Isabel Blancas
Breast Cancer
Evaluation of the Informational Content of Setup Verification Images for Patients Receiving Breast Radiation Therapy (Anterior EPI)
The purpose of this study is to determine if an alternative imaging protocol done at the time of radiotherapy treatments for patients with breast cancer can improve accuracy in patient set-up.
- Trial name
- Anterior EPI (NCT00800189)
- Testing
- Anterior electronic portal images (EPI)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice.
- Trial name
- NCT01152606
- Testing
- trastuzumab [Herceptin]
- Where
- 205 sites in Austria, Belgium and 7 more
- Volunteers
- 3,942 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.